Trending NewsTrending NewsNASDAQ:BMEA Biomea Fusion (BMEA) Stock Price, News & Analysis $1.76 -0.92 (-34.27%) As of 11:18 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biomea Fusion Stock (NASDAQ:BMEA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Biomea Fusion alerts:Sign Up Key Stats Today's Range$1.70▼$2.0150-Day Range$1.53▼$2.6752-Week Range$1.29▼$13.07Volume11.99 million shsAverage Volume1.37 million shsMarket Capitalization$104.44 millionP/E RatioN/ADividend YieldN/APrice Target$9.50Consensus RatingModerate Buy Company Overview Biomea Fusion, Inc. (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors. The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction. BMF-219 is currently undergoing early-phase clinical evaluation in patients with MLL-rearranged leukemias and other malignancies driven by dysregulated menin activity. In parallel, Biomea Fusion is advancing a pipeline of preclinical programs targeting additional epigenetic and chromatin-associated proteins, all developed using its integrated discovery platform. Founded in 2018, Biomea Fusion has assembled a multidisciplinary team of drug discovery scientists, clinical development experts and regulatory specialists. The company conducts its research and early clinical operations in the United States and is actively exploring collaborations to support later‐stage development and global commercialization. With its focus on epigenetic modulation in oncology, Biomea Fusion seeks to deliver novel treatment options for patients facing unmet medical needs.AI Generated. May Contain Errors. Read More Biomea Fusion Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreBMEA MarketRank™: Biomea Fusion scored higher than 68% of companies evaluated by MarketBeat, and ranked 320th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingBiomea Fusion has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialBiomea Fusion has a consensus price target of $9.50, representing about 255.8% upside from its current price of $2.67.Amount of Analyst CoverageBiomea Fusion has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Biomea Fusion's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biomea Fusion are expected to grow in the coming year, from ($3.93) to ($3.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomea Fusion is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomea Fusion is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomea Fusion has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biomea Fusion's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.68% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Biomea Fusion has recently decreased by 2.86%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomea Fusion does not currently pay a dividend.Dividend GrowthBiomea Fusion does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.68% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Biomea Fusion has recently decreased by 2.86%, indicating that investor sentiment is improving. News and Social Media3.0 / 5News Sentiment0.36 News SentimentBiomea Fusion has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Biomea Fusion this week, compared to 3 articles on an average week.Search Interest38 people have searched for BMEA on MarketBeat in the last 30 days. This is an increase of 138% compared to the previous 30 days.MarketBeat Follows18 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is an increase of 64% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biomea Fusion insiders have not sold or bought any company stock.Percentage Held by Insiders18.42% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biomea Fusion's insider trading history. Receive BMEA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMEA Stock News HeadlinesBiomea's diabetes drug shows promise, may work for those not responding to GLP-11 hour ago | msn.comBiomea Fusion Announces Positive Phase II Study Results1 hour ago | msn.comURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash before 2025 ends.October 7 at 2:00 AM | StockEarnings (Ad)Biomea Fusion announces offering of common stock and warrants, no amount given1 hour ago | msn.comBiomea Fusion rises after results from type 2 diabetes drug1 hour ago | msn.comBiomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct ...1 hour ago | theglobeandmail.comBiomea Fusion Announces Pricing of Public Offering of Securities4 hours ago | globenewswire.comBiomea Fusion Reports Positive 52-Week Results from Phase II COVALENT-111 Study of Icovamenib in Type 2 Diabetes PatientsOctober 6 at 4:31 PM | quiverquant.comQSee More Headlines BMEA Stock Analysis - Frequently Asked Questions How have BMEA shares performed this year? Biomea Fusion's stock was trading at $3.88 at the beginning of 2025. Since then, BMEA stock has decreased by 31.2% and is now trading at $2.67. How were Biomea Fusion's earnings last quarter? Biomea Fusion, Inc. (NASDAQ:BMEA) released its quarterly earnings data on Tuesday, August, 5th. The company reported ($0.51) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.08. When did Biomea Fusion IPO? Biomea Fusion (BMEA) raised $120 million in an IPO on Friday, April 16th 2021. The company issued 7,500,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO. How do I buy shares of Biomea Fusion? Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biomea Fusion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biomea Fusion investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings8/05/2025Today10/07/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BMEA CIK1840439 Webwww.biomeafusion.com Phone650-980-9099FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Price Target for Biomea Fusion$9.50 High Price Target$18.00 Low Price Target$3.00 Potential Upside/Downside+255.8%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($3.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$138.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-243.95% Return on Assets-140.74% Debt Debt-to-Equity RatioN/A Current Ratio3.68 Quick Ratio3.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book1.88Miscellaneous Outstanding Shares59,510,000Free Float48,547,000Market Cap$158.89 million OptionableOptionable Beta-0.12 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:BMEA) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.